Pipeline Insight - Orphan Diseases in Neurology - Part III - Myasthenia Gravis - http://www.companiesandmarkets.com adds new report

2008-11-20 03:37:02 - Pipeline Insight - Orphan Diseases in Neurology - Part III - Myasthenia Gravis - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/Pipeline-Insig ..

Introduction

The myasthenia gravis market is set to grow from $44m in 2007 to $239m in 2017 across the seven major pharmaceutical markets in Datamonitor´s base scenario forecast. Amarin´s pipeline candidate EN101 is forecast to become the market leading brand with sales of $153m in 2017.

Scope

*Scenario based analysis and forecasts of the commercial potential of the myasthenia gravis market to 2017.

*Analysis of the patient potential, commercial viability, and unmet needs of the myasthenia gravis market.

*Indication-specific sales forecasts of marketed and pipeline drugs to 2017.

*Assessment of the treatment algorithms used in this disease.

Highlights

Although myasthenia gravis is an uncommon disease (106,000 patients across the seven major markets), it is more prevalent than Huntington´s disease or amyotrophic lateral sclerosis (31,000 and 34,000 patients, respectively), both orphan neurological diseases with larger late-stage pipelines.

In the majority of patients, symptoms can be well controlled with current treatments. However, very poor side-effect profiles and inconvenient dosing regimens of these therapies impact on the patient´s quality of life, and represent key unmet needs in myasthenia gravis treatment.

Amarin´s EN101 is forecast to become the market leading brand with sales of $153m in 2017 in Datamonitor´s base scenario. In an alternative scenario EN101 proves to be steroid sparing enhancing its commercial potential ($621m in 2017). However, poor bioavailability of RNA therapies enhances the risk of EN101 failing in larger scale trials.

Reasons to Purchase

*Access the lucrative potential of this underdeveloped neurological auto-immune disease.

*Benchmark key late-stage compounds against current leading therapies.

*Understand the opportunities in this market based on the comments of interviewed key opinion leaders.